Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Caliper Strike Co-Marketing Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences and Illumina will co-market Caliper's library sample preparation and analysis and quality control tools with Illumina's genome sequencing platforms, Caliper said today.

Caliper said the firms have signed an agreement covering marketing for its LabChip XT library preparation tool and its LabChip GX quality control platform for use with Illumina's Genome Analyzer and HiSeq2000 systems.

The LabChip XT is used to replace gel isolation steps in the sequencing library prep process, and the GX uses microfluidics technology to perform electrophoretic separations for analyzing DNA or RNA size, concentration, or integrity.

"The LabChip XT in particular was developed with direct input from Illumina and we are excited to enter into this co-marketing agreement to promote both LabChip products to address critical bottlenecks in sample preparation of next-generation sequencing libraries," Caliper CEO and President Kevin Hrusovsky said in a statement.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.